Literature DB >> 23319908

Sodium oxybate intolerance associated with familial serum acylcarnitine elevation.

Jon Berner1.   

Abstract

Our case describes clinical features of two families defined by joint phenotypes: sodium oxybate intolerance and elevated serum acylcarnitines. Oxybate intolerance variably presents as either cervical dystonia or sleep-related eating disorder. Our objective is to identify biological markers which predict a poor response to sodium oxybate as a treatment for disturbed sleep. Familial inheritance pattern, genotype analysis, multiorgan system involvement, and response to treatment suggest the presence of a secondary cause of fatty oxidation defect, i.e., mitochondrial disorder. Our case report supports the possible conclusion that variance in human mitochondrial metabolism may affect sodium oxybate tolerability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319908      PMCID: PMC3525992          DOI: 10.5664/jcsm.2346

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  8 in total

1.  Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues.

Authors:  Alexandra Latini; Cleide Gonçalves da Silva; Gustavo C Ferreira; Patrícia F Schuck; Karina Scussiato; João J Sarkis; Carlos S Dutra Filho; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner
Journal:  Mol Genet Metab       Date:  2005-06-15       Impact factor: 4.797

2.  Immunohistochemical localization of a GHB receptor-like protein isolated from rat brain.

Authors:  Véronique Kemmel; Monique Miehe; Guy Roussel; Omar Taleb; Karine Nail-Boucherie; Christiane Marchand; Christine Stutz; Christian Andriamampandry; Dominique Aunis; Michel Maitre
Journal:  J Comp Neurol       Date:  2006-10-01       Impact factor: 3.215

3.  Sodium oxybate-induced sleep driving and sleep-related eating disorder.

Authors:  Douglas McKay Wallace; Tanisha Maze; Shirin Shafazand
Journal:  J Clin Sleep Med       Date:  2011-06-15       Impact factor: 4.062

4.  Differential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation.

Authors:  Julie Vienne; Bernhard Bettler; Paul Franken; Mehdi Tafti
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

5.  Clinical and pharmacokinetic aspects of high dose oral baclofen therapy.

Authors:  M L Aisen; M A Dietz; P Rossi; J M Cedarbaum; H Kutt
Journal:  J Am Paraplegia Soc       Date:  1992-10

6.  ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.

Authors:  Rikke K J Olsen; Simon E Olpin; Brage S Andresen; Zofia H Miedzybrodzka; Morteza Pourfarzam; Begoña Merinero; Frank E Frerman; Michael W Beresford; John C S Dean; Nanna Cornelius; Oluf Andersen; Anders Oldfors; Elisabeth Holme; Niels Gregersen; Douglass M Turnbull; Andrew A M Morris
Journal:  Brain       Date:  2007-06-20       Impact factor: 13.501

7.  Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial.

Authors:  I Jon Russell; A Thomas Perkins; Joel E Michalek
Journal:  Arthritis Rheum       Date:  2009-01

8.  Enhanced hypothalamic glucose sensing in obesity: alteration of redox signaling.

Authors:  Anne-Laure Colombani; Lionel Carneiro; Alexandre Benani; Anne Galinier; Tristan Jaillard; Thibaut Duparc; Géraldine Offer; Anne Lorsignol; Christophe Magnan; Louis Casteilla; Luc Pénicaud; Corinne Leloup
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

  8 in total
  1 in total

1.  Restless Eating, Restless Legs, and Sleep Related Eating Disorder.

Authors:  Michael J Howell
Journal:  Curr Obes Rep       Date:  2014-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.